🎉 OBI-902 receives a Second FDA Orphan Drug Designation, this time for gastric cancer including gastroesophageal junction adenocarcinoma.
We remain committed to advancing OBI-902 in areas of high unmet medical need. 🔬
#ADC #OBI902 #TROP2 #GlycOBI #ODD #GC #GEJC

www.obipharma.com/news/obi-902...

WELCOME To #ESMO25: The OncoAlert #GICancer Faculty, led by Dr. Akkus🇹🇷 , Dr. Hornstein🇺🇸 , Dr. Balsa🇪🇸 , Dr. Cifuentes 🇨🇴 & Dr. Morgan🇺🇸 have selected the OncoAlert TOP 🔟 #ESMO25 Abstracts In #CRC , #HCC, #GEJC #ColonCancer to be presented in Berlin🇩🇪 Picked using a Delphi System to establish our picks.

The OncoAlert #GICancer Faculty, led by Dr. Akkus🇹🇷 , Dr. Hornstein🇺🇸 , Dr. Balsa🇪🇸 , Dr. Cifuentes 🇨🇴 & Dr. Morgan🇺🇸 have selected the OncoAlert TOP 🔟 #ESMO25 Abstracts In #CRC , #HCC, #GEJC #ColonCancer to be presented in Berlin🇩🇪 Picked using a Delphi System to establish our picks.

Lonsurf (trifluridine/tipiracil) 2025 Updates: Uses in Cancer, Side Effects, Dosage, Expectations, and More - OncoDaily Lonsurf (trifluridine/tipiracil) is approved to treat gastric/ GEJ and CRC cancers. This article explores its uses , side effects, dosage, expectations.

Lonsurf (trifluridine/tipiracil) 2025 Updates: Uses in Cancer, Side Effects, Dosage, Expectations, and More

oncodaily.com/drugs/lonsur...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Lonsurf #GEJC #GastricCancer #GIOnc